ODC1 Genotype-Guided Polyamine Inhibition for Colorectal Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer chemoprevention methods face challenges due to marginal agent efficacy and toxicities, particularly in treating and preventing colorectal cancers, where identifying suitable genetic markers for treatment is crucial for personalized medicine.
Innovation Solution
A method involving genetic testing to determine a patient's genotype at position +316 of the ODC1 promoter gene allele, followed by administering a combination of an ornithine decarboxylase inhibitor and a polyamine pathway modulator, such as α-difluoromethylornithine and a non-aspirin containing NSAID, to tailor treatment based on the patient's genetic profile.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polyamine-inhibitory combination therapy (DFMO and sulindac) is administered to colorectal adenoma patients, then adenoma recurrence is reduced, but ototoxicity and cardiovascular events increase
Solution Approach 1:
The patent applies local quality by tailoring the treatment approach to specific patient subgroups based on their ODC1 genotype. Patients with the ODC1 GG genotype receive the full polyamine-inhibitory combination therapy (DFMO and sulindac), while patients with ODC1 non-GG genotypes receive alternative treatments. This genotype-specific customization optimizes therapeutic benefit while minimizing harmful effects in each patient subgroup.
Solution Approach 2:
The patent changes the treatment parameter (therapy regimen) based on the genetic parameter (ODC1 genotype). By identifying patients with specific genetic characteristics through ODC1 genotyping, the treatment approach is adjusted to match the patient's metabolic profile, thereby improving efficacy and reducing toxicity for each genetic subgroup.
2Adaptability or versatility
If ODC1 genotyping is performed to guide treatment selection, then treatment suitability is optimized, but diagnostic complexity increases
Solution Approach 1:
The patent replaces complex clinical judgment and trial-and-error treatment selection with a straightforward genetic test (ODC1 genotyping). This molecular diagnostic approach substitutes for complicated diagnostic workflows and enables automated, objective treatment assignment based on genotype results, thereby simplifying the overall decision-making process despite the added genetic testing step.
3Object-affected harmful factors
If personalized treatment based on ODC1 genotype is implemented, then toxicities are minimized, but treatment protocol complexity increases
Solution Approach 1:
The patent segments the patient population into distinct genotype-based subgroups (ODC1 GG versus ODC1 non-GG) and assigns different treatment protocols to each segment. This segmentation allows for simplified, standardized treatment within each subgroup while managing overall protocol complexity through clear genotype-based decision rules.
Data Source
AI summary
The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection.